Board and Management
Learn more about Race Oncology’s board of directors and the management team.
Dr Peter Smith
Executive Chair
Dr Peter Smith has over 30 years of experience in the pharmaceutical and biotech industry, with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies.
He was previously the CEO of private biotechnology company Myrio Therapeutics, and publicly listed Australian companies Alchemia and AMRAD.
Prior to moving to Australia, Peter co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ IPOs, fundraisings, and M&A.
His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. In addition to serving as a Director of Race Oncology, he is also currently a Director of MycRx Inc., and Amala Therapeutics.
To view Dr Smith’s LinkedIn profile, please click here.
Dr Serge Scrofani
Non-Executive Director
Dr Serge Scrofani has more than 28 years’ experience in the healthcare sector, working in global roles across research and strategy, and corporate and business development. He served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a pivotal role in multiple strategic initiatives including the company’s global COVID-19 response and its $US11.7 billion acquisition of Vifor Pharma AG. Prior to this, he led Business Development for subsidiary CSL Behring, based in the US.
Serge is currently Principal for Poplar Advisory, a boutique strategic advisory firm focused on the healthcare sector. He is also a Board member of the Burnet Institute and The Centre for Eye Research, and founding Director of private equity firm FinCap Pty Ltd.
After obtaining his PhD in Structural Biology from La Trobe University, Serge undertook postdoctoral research studies at The University of Melbourne and completed a Fulbright postdoctoral fellowship at The Scripps Research Institute, La Jolla California. He also holds an MBA from the Melbourne Business School.
To view Dr Serge Scrofani’s LinkedIn profile, please click here.
Dr Megan Baldwin
Non-Executive Director
Dr Baldwin has more than 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications. She is the Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT). During her tenure of 10 years as CEO and Managing Director of Opthea, the company’s lead asset was advanced through preclinical studies to global Phase 3 registrational trials.
Prior to Opthea, Dr Baldwin was previously employed at Genentech (now Roche) as a researcher before moving to Genentech’s commercial division. Dr Baldwin’s experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentech’s early stage oncology programs.
Dr Baldwin currently serves on the boards of Anaxis Pharma and Gertrude Biomedical, and is a director of Ausbiotech. She holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research.
To view Dr Baldwin’s LinkedIn profile, please click here.
Dr Daniel Tillett
Managing Director and Chief Executive Officer
Dr Daniel Tillett is the Managing Director and Chief Executive Officer of Race Oncology. He is a veteran executive in the biotech industry with more than 25 years of management experience and leadership in all aspects of commercial operations including strategy, IP management, sales and marketing, project management, licensing and fundraising.
Dr Tillett is also the founder and CEO of Nucleics, a private Australian biotechnology company producing and selling world-leading DNA sequencing software to the genomics industry. Nucleics SAAS (software as a service) genomics tools are used in more than 30 countries and at over 250 companies and research institutions.
Previously, he was a Senior Lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, virology, microbiology, bioinformatics and cancer.
Dr Tillett has a BSc (Hons 1) and PhD from the University of New South Wales in Molecular Genetics and Biochemistry. He has more than 40 scientific publications and granted patents in molecular biology, virology, microbiology, genetics and biochemistry.
To view Dr Daniel Tillett’s LinkedIn profile, please click here.
